|
Title
|
|
|
|
The administration of methotrexate in patients with Still's disease, "real-life" findings from AIDA Network Still Disease Registry
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Objectives: To describe clinical characteristics of patients with Still's disease treated with methotrexate (MTX) and to assess drug effectiveness evaluating change in disease activity, reduction of inflammatory markers, and glucocorticoid (GC)-sparing effect. Methods: Patients with Still's disease treated with MTX were assessed among those included in AIDA Network Still Disease Registry.Results: In this registry, 171 patients with Still's disease were treated with MTX (males 43.3%, age 37.1 & PLUSMN; 16.0 years). They were mainly characterised by joint features and fever without a prominent multiorgan involvement. MTX was administered with GCs in 68.4% of patients, with other conventional synthetic DMARDs in 6.4%, and with biologic DMARDs in 25.1%. A significant reduction of the modified systemic score was observed, and 38.6% patients were codified as being in clinical remission at the end of follow-up. The concomitant administration of a biologic DMARD resulted a predictor of the clinical remission. Furthermore, a reduction of inflammatory markers and ferritin levels was observed following the administration of MTX. Additionally, a marked reduction of the dosage of concomitant GCs was identified, while 36.7% discontinued such drugs. Male gender appeared as a predictor of GC discontinuation. MTX was discontinued in 12.3% of patients because of adverse effects, and in 12.3% for lack of efficacy.Conclusions: Clinical characteristics of patients with Still's disease treated with MTX were described, mainly joint features and fever without a prominent multiorgan involvement. The clinical usefulness of MTX was reported in reducing the disease activity, decreasing the inflammatory markers, and as GC-sparing agent. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Seminars in arthritis and rheumatism. - Orlando, Fla
| |
|
Publication
|
|
|
|
Orlando, Fla
:
2023
| |
|
ISSN
|
|
|
|
0049-0172
| |
|
DOI
|
|
|
|
10.1016/J.SEMARTHRIT.2023.152244
| |
|
Volume/pages
|
|
|
|
62
(2023)
, p. 1-9
| |
|
Article Reference
|
|
|
|
152244
| |
|
ISI
|
|
|
|
001054979100001
| |
|
Pubmed ID
|
|
|
|
37517110
| |
|
Medium
|
|
|
|
E-only publicatie
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (open access)
|
|
|
|
| |
|